Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: margie who wrote (2439)	10/21/1997 5:18:00 PM
From: Steve Fancy	Read Replies (2) \| Respond to of 6136

Hello Margie. Thanks for the response regarding sales estimates. If in fact future European sales are not factored in, do we expect that analyst estimates jump dramatically upon approval? If it were all this cut and dry, you would expect that a percentage of the potential upside would already be priced into the stock, yet it does not seem to be. Assuming approval this calendar year, and hopefully worst case, shipping by fiscal Q2, I wonder what we could estimate European sales to be for three quarters? Sounds like the actual approval, or more likely, strong rumors of when it will happen, will be what propel's the stock towards 70. As I'm thinking aloud, I realized that that is what happened with the US approval. Huge runup on rumors of approval soon, then significant pull back after approval. sf